Effect of virulence on immunogenicity of single and double vaccinia virus recombinants expressing differently immunogenic antigens: antibody-response inhibition induced by immunization with a mixture of recombinants differing in virulence
It has been shown recently that the residual virulence of vaccinia virus (VV) is an important factor that influences the outcome of immunization with VV recombinants. This study focused on the correlation of the residual virulence of several VV recombinants with antibody responses against the strongly immunogenic extrinsic glycoprotein E of varicella-zoster virus and the weakly immunogenic extrinsic protein preS2–S of hepatitis B virus and against VV proteins, with mice used as a model organism. Furthermore, the effects of mixing different recombinants on the antibody response were studied. The results obtained indicated that: (i) the antibody response depended on the residual virulence of the recombinants, more so in the case of the weakly immunogenic protein; (ii) the residual virulence, the growth rate of the VV recombinants in extraneural tissues and the immunogenicity were associated features; (iii) immunization with mixtures of two differently virulent recombinants or with unequal amounts of two similarly virulent recombinants sometimes led to the suppression of antibody response. The appearance of this suppression was dependent on three factors: the residual virulence of the recombinants, the immunogenicity of the extrinsic proteins and the ratio of the recombinants in the mixtures. Thus, the data obtained demonstrate that there are various limitations to the use of replicating VV recombinants for immunization purposes.
BullerR. M. L.,
PalumboG. J.1992; Safety and attenuation of vaccinia virus. In Recombinant Poxviruses pp. 235–267 Edited by
BinnsM.,
SmithG.
London: CRC Press;
GiavedoniL.,
JonesL.,
MebusC.,
YilmaT.1991; A vaccinia virus double recombinant expressing the F and H genes of rinderpest virus protects cattle against rinderpest and causes no pock lesions. Proceedings of the National Academy of Sciences USA888011–8015
KutinováL.,
LudvíkováV.,
SimonováV.,
OtavováM.,
KryštofováJ.,
HainzP.,
PressM.,
KunkeD.,
VonkaV.1995; Search for optimal parent for recombinant vaccinia virus vaccines. Study of three vaccinia virus vaccinal strains and several virus lines derived from them. Vaccine 13:487–493
KutinováL.,
LudvíkováV.,
KryštofováJ.,
OtavováM.,
SimonováV.,
Němeč kováŠ.,
HainzP.,
VonkaV.1996; Influence of the parental virus strain on the virulence and immunogenicity of recombinant vaccinia viruses expressing HBV preS2-S protein or VZV glycoprotein I.. Vaccine 14:1045–1052
KutinováL.,
LudvíkováV.,
Němeč kováŠ.,
HainzP.,
SimonováV.,
VonkaV.1999; Secondary vaccination with vaccinia virus recombinants: role of residual virulence of recombinants and immunogenicity of extrinsic antigens. Vaccine 17:1186–1192
LeeM. S.,
RoosJ. M.,
McGuiganL. C.,
SmithK. A.,
CormierN.,
CohenL. K.,
RobertsB. E.,
PayneL. G.1992; Molecular attenuation of vaccinia virus: mutant generation and animal characterization. Journal of Virology 66:2617–2630
Ludvíkov áV.,
KunkeD.,
HamšíkováE.,
KutinováL.,
VonkaV.1991; Immunogenicity in mice of varicella- zoster virus glycoprotein I expressed by a vaccinia virus–varicella-zoster virus recombinant. Journal of General Virology 72:1445–1449
MossB.1996; Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proceedings of the National Academy of Sciences USA 93:11341–11348
MossB.,
RosenblumE. N.,
GrimleyP. M.1971; Assembly of virus particles during mixed infection with wild-type vaccinia and a rifampicin-resistant mutant. Virology 45:135–148
Němečkováš.,
KutinováL.,
HamšíkováE.,
KunkeD.,
PressM.,
ZávadováH.,
SmrtJ.,
VonkaV.1991; Synthesis and immunogenicity of hepatitis B virus envelope antigen expressed by recombinant vaccinia virus. Finding of retention signal in the C-terminal portion of the preS1 domain of subtype adyw. Archives of Virology 121:29–41
Němečkováš.,
LudvíkováV.,
MarešováL.,
KryštofováJ.,
HainzP.,
KutinováL.1996; Induction of varicella-zoster virus-neutralizing antibodies in mice by co-infection with recombinant vaccinia viruses expressing the gH or gL gene.. Journal of General Virology 77:211–215
PerkusM. E.,
TartagliaJ.,
PaolettiE.1995; Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases.. Journal of Leukocyte Biology 58:1–13
RodriguezD.,
RodriguezJ. R.,
RodriguezJ. F.,
TrauberD.,
EstebanM.1989; Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. Proceedings of the National Academy of Sciences USA 86:1287–1291
ShidaH.,
MatsumotoS.1983; Analysis of the hemagglutinin glycoprotein from mutants of vaccinia virus that accumulates on the nuclear envelope. Cell 33:423–434
ShidaH.,
HinumaY.,
HatanakaM.,
MoritaM.,
KidokoroM.,
SuzukiK.,
MaruyamaT.,
Takahashi-NishimakiF.,
SugimotoM.,
KitamuraR.,
MiyazawaT.,
HayamiM.1988; Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene. Journal of Virology 62:4474–4480
TartagliaJ.,
PerkusM. E.,
TaylorJ.,
NortonE. K.,
AudonnetJ. C.,
CoxW. I.,
DavisS. W.,
van der HoevenJ.,
MeignierB.,
RiviereM.,
LanguetB.,
PaolettiE.1992; NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217–232
TineJ. A.,
LanarD. E.,
SmithD. M.,
WelldeB. T.,
SchultheissP.,
WareL. A.,
KauffmanE. B.,
WirtzR. A.,
De TaisneC.,
HuiG. S. N.,
ChangS. P.,
ChurchP.,
HollingdaleM. R.,
KaslowD. C.,
HoffmanS.,
GuitoK. P.,
BallouW. R.,
SadoffJ. C.,
PaolettiE.1996; NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infection and Immunity 64:3833–3844
WildT. F.,
BernardA.,
SpehnerD.,
DrillienR.1992; Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice. Journal of General Virology 73:359–367
Effect of virulence on immunogenicity of single and double vaccinia virus recombinants expressing differently immunogenic antigens: antibody-response inhibition induced by immunization with a mixture of recombinants differing in virulence